Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
F60087CI101
Phase 2 other active
Quick answer
Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs) for locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs) is a Phase 2 program (other) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pierre Fabre Medicament
- Indication
- locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
- Phase
- Phase 2
- Modality
- other
- Status
- active